Equity in Access Research Grants

Funding Agency:
Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society’s (LLS) Equity in Access Research Program was created to help ensure more equitable access to care for blood cancer patients and survivors.

Through this program, LLS aims to generate new evidence that can guide policy reform and changes in healthcare practice, in order to mitigate the impact of the social, economic and environmental disadvantages and reduce barriers to care. 

LLS invites letters of intent for the Equity in Access Research Program under our Request for Proposals: Understanding How Health Insurance Affects Equity in Access to Care for Patients with and Survivors of Blood Cancer.



  • Required Letter of Intent: Sep. 16, 2022
  • Invited Full Application: Jan. 13, 2023

Agency Website

Eligibility Requirements

LLS welcomes Principal Investigators at all stages of their careers as well as Principal Investigators who have not previously conducted research in the area of blood cancer. Principal Investigator(s) must meet the following eligibility criteria:

• The Principal Investigator(s) must be affiliated with a public or nonprofit institution (tax exempt under Section 501(c)(3) of the Internal Revenue Code).

• The sponsoring institution must be based in the United States or its territories.

• The Principal Investigator must have a PhD, MD, ScD, JD, or equivalent doctoral degree.  

The Principal Investigator and other study team members may come from a variety of disciplines, including but not limited to health services research, public health, economics, sociology, public policy, political science, public administration, medicine, and law. We encourage multi-disciplinary teams. 

Funding Type



Junior Faculty
Post Doctoral Fellows


Medical - Clinical Science
Medical - Translational
Social Sciences

External Deadline

September 16, 2022